• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cocrystal Pharma Inc.

    5/27/26 4:32:01 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COCP alert in real time by email
    DEFA14A 1 formdefa14-a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under §240.14a-12

     

    Cocrystal Pharma, Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
       
    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      (1) Title of each class of securities to which transaction applies:
         
      (2) Aggregate number of securities to which transaction applies:
         
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
         
      (4) Proposed maximum aggregate value of transaction:
         
      (5) Total fee paid:
         

     

    ☐ Fee paid previously with preliminary materials.
       
    ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

      (1) Amount Previously Paid:
         
      (2) Form, Schedule or Registration Statement No.:
         
      (3) Filing Party:
         
      (4) Date Filed:

     

     

     

     

     

     

    CONTROL ID:

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE COCRYSTAL PHARMA, INC. 2026 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JULY 14, 2026

     

    DATE: July 14, 2026    
         
    TIME: AT 11:00 AM ET    
         
    LOCATION: To be held virtually by calling 877-407-3088 (toll free).    

     

    THIS COMMUNICATION IS NOT A FORM OF VOTING AND ONLY REPRESENTS A NOTICE TO ACCESS A MORE COMPLETE SET OF PROXY MATERIALS (INCLUDING THE PROXY STATEMENT AND FORM 10-K) AVAILABLE TO YOU ON THE INTERNET. WE ENCOURAGE YOU TO ACCESS AND REVIEW ALL OF THE IMPORTANT INFORMATION CONTAINED IN THE PROXY MATERIALS BEFORE VOTING. THE PROXY MATERIALS ARE AVAILABLE AT www.COCP.vote To submit your proxy while visiting this site, you will need the control ID in THIS NOTICE.

     

      ● IF YOU DECIDE TO VIEW THE PROXY MATERIALS AND VOTE YOUR SHARES ONLINE,
         
        Step 1: Go to www.COCP.vote
        Step 2: To view or download the proxy materials, click on the link that describes the material you wish to view or download. For example, to view or download the Proxy Statement, click on the “Proxy Statement” link.
        Step 3: To vote online, click on the designated link and follow the on-screen instructions. YOU MAY VOTE ONLINE UNTIL 11:59 PM EASTERN TIME ON July 13, 2026.
         
      ● IF YOU WANT TO RECEIVE A PAPER COPY OF THE PROXY MATERIALS INCLUDING THE PROXY CARD, YOU MUST REQUEST ONE. THERE IS NO CHARGE TO YOU FOR REQUESTING A COPY. TO FACILITATE TIMELY DELIVERY PLEASE MAKE THE REQUEST, AS INSTRUCTED BELOW, BEFORE JUNE 30, 2026.

     

     

    HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

     

         
                 
    PHONE:   FAX:   INTERNET:   EMAIL:
                 
    CALL TOLL FREE   SEND THIS CARD TO   www.COCP.vote   proxy@equitystock.com
                 
    1-212-575-5757   347-584-3644  

    FOLLOW THE ON-SCREEN

    INSTRUCTIONS.

     

    INCLUDE YOUR CONTROL

    ID IN YOUR EMAIL.

     

     

     

     

     

    Voting items

     

    The board of directors of COCRYSTAL PHARMA, INC. (the “company”) recommends that you vote “for” FOR EACH OF THE NOMINEES IN PROPOSAL 1, “FOR” ON PROPOSALS 2, 3, and 4

     

    1. Elect five directors for a one-year term expiring at the next annual meeting of stockholders.

     

    2. Ratify the selection of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

     

    3. Approve an adjournment of the Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote at the Annual Meeting.

     

    Note: To transact such other business as may be properly brought before the Annual Meeting and any adjournments thereof.

     

    THE BOARD OF DIRECTORS HAS FIXED THE CLOSE OF BUSINESS ON MAY 19, 2026, AS THE RECORD DATE FOR THE DETERMINATION OF MEMBERS ENTITLED TO RECEIVE NOTICE OF THE ANNUAL MEETING AND TO VOTE THE COMPANY’S COMMON SHARES THEY HELD ON THAT DATE AT THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT OF THE MEETING.

     

    PLEASE NOTE–THIS IS NOT A PROXY CARD - YOU CANNOT VOTE BY RETURNING THIS CARD. TO VOTE YOUR SHARES, YOU MUST VOTE ONLINE OR REQUEST A PAPER COPY OF PROXY MATERIALS TO RECEIVE A PROXY CARD.

     

    IF YOU WISH TO ATTEND AND VOTE AT THE MEETING, PLEASE FOLLOW INSTRUCTIONS LISTED ON THE REVERSE SIDE.

     

    YOUR VOTE IS IMPORTANT!

     

     

     

     

    Get the next $COCP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COCP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COCP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

    BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continu

    6/3/26 7:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

    Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the

    5/26/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

    Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohortsHighlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026Granted FDA Fast Track designation for CDI-988, enabling the potential for an accelerated development pathwayReceived initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides updates on its antiviral product pipeline and business activities and reports financial results

    5/15/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Frost Phillip Md Et Al bought $19,952 worth of shares (20,000 units at $1.00) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/25/26 4:10:11 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Frost Phillip Md Et Al bought $47,280 worth of shares (50,000 units at $0.95) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/9/26 4:10:05 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Frost Phillip Md Et Al bought $47,275 worth of shares (50,000 units at $0.95) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    1/2/26 4:10:19 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    SEC Filings

    View All

    Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

    6/3/26 7:00:17 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Cocrystal Pharma Inc.

    DEFA14A - Cocrystal Pharma, Inc. (0001412486) (Filer)

    5/27/26 4:32:01 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cocrystal Pharma Inc.

    DEF 14A - Cocrystal Pharma, Inc. (0001412486) (Filer)

    5/27/26 4:30:44 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Sapirstein James

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    6/3/26 4:10:45 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sapirstein James

    3 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    6/3/26 4:10:13 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Frost Phillip Md Et Al bought $19,952 worth of shares (20,000 units at $1.00) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/25/26 4:10:11 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    Leadership Updates

    Live Leadership Updates

    View All

    Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

    BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continu

    6/3/26 7:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

    Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (the "Company" or "Cocrystal") announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered warrants to purchase up to 1,486,048 shares of common stock at an exercise price of $1.24 per share. The warrants are exercisable upon issuance and will expire in 27 months. The four Investors in th

    10/30/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

    BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six. Mr. Hassan's distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms. Earlier this month, Cocrystal announced Mr. Hassan's $2 million investment in the Company through an at-the-market private placement. "It's an honor to attract such a highly accomplished industry veteran to our Board," said Roger Kornberg, PhD, Cocrystal Chairman, Chief Scientist and Chairman of the Scient

    4/24/23 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cocrystal Pharma Inc. (Amendment)

    SC 13G/A - Cocrystal Pharma, Inc. (0001412486) (Subject)

    1/2/24 9:53:56 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Cocrystal Pharma Inc. (Amendment)

    SC 13D/A - Cocrystal Pharma, Inc. (0001412486) (Subject)

    4/14/23 4:01:17 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cocrystal Pharma Inc.

    SC 13G - Cocrystal Pharma, Inc. (0001412486) (Subject)

    4/12/23 4:09:56 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COCP
    Financials

    Live finance-specific insights

    View All

    Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

    Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohortsHighlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026Granted FDA Fast Track designation for CDI-988, enabling the potential for an accelerated development pathwayReceived initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides updates on its antiviral product pipeline and business activities and reports financial results

    5/15/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the year ended December 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "We are delighted to report that our norovirus human

    3/31/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and treatment," said Sam Lee, Ph.D., Cocrystal's President and co-CEO. "We are encouraged by the favorable

    8/14/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care